TScan Therapeutics announced a workforce reduction of roughly 30% and the discontinuation of a Phase I solid‑tumor T‑cell receptor (TCR) trial, shifting focus to hematologic indications. The company said it is refocusing resources on blood‑cancer programs where earlier signals and competitive dynamics are more favorable. The restructuring follows strategic reviews and reflects industry pressures on cell‑therapy developers to prioritize programs with clearer regulatory paths and market prospects. TScan will realign R&D and corporate functions to support the revised pipeline. The move underscores consolidation risk among smaller immunotherapy developers and may prompt partnering or sale of shelved assets.